Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers
- PMID: 28868181
- PMCID: PMC5561432
- DOI: 10.4291/wjgp.v8.i3.117
Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers
Abstract
Aim: To determine if 30-d of oral spore-based probiotic supplementation could reduce dietary endotoxemia.
Methods: Apparently healthy men and women (n = 75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered "responders" and were randomized to receive either placebo (rice flour) or a commercial spore-based probiotic supplement [Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii] for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays (Luminex and Milliplex) as secondary, exploratory measures.
Results: Data were statistically analyzed using repeated measures ANOVA and a P < 0.05. We found that spore-based probiotic supplementation was associated with a 42% reduction in endotoxin (12.9 ± 3.5 vs 6.1 ± 2.6, P = 0.011) and 24% reduction in triglyceride (212 ± 28 vs 138 ± 12, P = 0.004) in the post-prandial period Placebo subjects presented with a 36% increase in endotoxin (10.3 ± 3.4 vs 15.4 ± 4.1, P = 0.011) and 5% decrease in triglycerides (191 ± 24 vs 186 ± 28, P = 0.004) over the same post-prandial period. We also found that spore-based probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (24.3 ± 2.2 vs 21.5 ± 1.7, P = 0.017) and IL-1β (1.9 ± 0.2 vs 1.6 ± 0.1, P = 0.020). Compared to placebo post supplementation, probiotic subject had less ghrelin (6.8 ± 0.4 vs 8.3 ± 1.1, P = 0.017) compared to placebo subjects.
Conclusion: The key findings of the present study is that oral spore-based probiotic supplementation reduced symptoms indicative of "leaky gut syndrome".
Keywords: Cardiovascular disease; Chronic disease; High-fat meal challenge; Inflammatory cytokines; Leaky gut syndrome; Metabolic endotoxemia; Multiplex; Probiotics.
Conflict of interest statement
Conflict-of-interest statement: The present study was funded in part by a competitive research grant from Microbiome Labs, LLC (Glenview, IL) to the University of North Texas. The UNT team did not receive direct funding associated with the completion of the present study. The funding agency was not involved in the data collection, analysis, interpretation, and manuscript preparation. Double blind procedures and confidentially were used to conduct the present study in a sound and unbiased manner. As such, the authors report no conflict of interest associated with completing the present study.
Figures
Similar articles
-
Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial.Integr Med (Encinitas). 2020 Apr;19(2):22-27. Integr Med (Encinitas). 2020. PMID: 33041703 Free PMC article.
-
Natural Endotoxemia in Dogs-A Hidden Condition That Can Be Treated with a Potential Probiotic Containing Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici: A Study Model.Animals (Basel). 2021 May 11;11(5):1367. doi: 10.3390/ani11051367. Animals (Basel). 2021. PMID: 34064947 Free PMC article.
-
Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial.Nutr J. 2021 Jun 1;20(1):47. doi: 10.1186/s12937-021-00703-7. Nutr J. 2021. PMID: 34074289 Free PMC article. Clinical Trial.
-
Treatment with a spore-based probiotic containing five strains of Bacillus induced changes in the metabolic activity and community composition of the gut microbiota in a SHIME® model of the human gastrointestinal system.Food Res Int. 2021 Nov;149:110676. doi: 10.1016/j.foodres.2021.110676. Epub 2021 Aug 30. Food Res Int. 2021. PMID: 34600678
-
Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier.Food Sci Biotechnol. 2019 Oct 8;28(5):1297-1305. doi: 10.1007/s10068-019-00691-9. eCollection 2019 Oct. Food Sci Biotechnol. 2019. PMID: 31695928 Free PMC article. Review.
Cited by
-
The Effects of Probiotic Bacillus Spores on Dexamethasone-Treated Rats.Int J Mol Sci. 2023 Oct 12;24(20):15111. doi: 10.3390/ijms242015111. Int J Mol Sci. 2023. PMID: 37894792 Free PMC article.
-
Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.Int J Mol Sci. 2023 Jul 7;24(13):11225. doi: 10.3390/ijms241311225. Int J Mol Sci. 2023. PMID: 37446403 Free PMC article. Clinical Trial.
-
Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19.Nutrients. 2023 Jan 17;15(3):488. doi: 10.3390/nu15030488. Nutrients. 2023. PMID: 36771194 Free PMC article.
-
The gut microbiome: a core regulator of metabolism.J Endocrinol. 2023 Jan 19;256(3):e220111. doi: 10.1530/JOE-22-0111. Print 2023 Mar 1. J Endocrinol. 2023. PMID: 36458804 Free PMC article. Review.
-
Prebiotic/probiotic supplementation resulted in reduced visceral fat and mRNA expression associated with adipose tissue inflammation, systemic inflammation, and chronic disease risk.Genes Nutr. 2022 Nov 28;17(1):15. doi: 10.1186/s12263-022-00718-7. Genes Nutr. 2022. PMID: 36437471 Free PMC article.
References
-
- Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, Machado JA, Correia MI, Cardoso VN. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr. 2011;50:261–269. - PubMed
-
- Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc. 2010;69:434–441. - PubMed
-
- Berni Canani R, Cucchiara S, Cuomo R, Pace F, Papale F. Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children. Eur Rev Med Pharmacol Sci. 2011;15:809–822. - PubMed
-
- Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033–1049; quiz 1050. - PubMed
-
- Anhê FF, Marette A. A microbial protein that alleviates metabolic syndrome. Nat Med. 2017;23:11–12. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
